Proton pump inhibitor modifies inflammatory reaction in human gastric mucosa infected by Helicobacter pylori.
OBJECTIVE
To examine whether proton pump inhibitors modify the production of oxygen-derived free radicals and related cytokines in the human gastric mucosa infected with H. pylori.


METHODS
Thirty-four H. pylori-positive peptic ulcer patients (23 gastric ulcer, 11 duodenal ulcer) were enrolled. Biopsy tissue samples were obtained endoscopically from the antrum and corpus. Tissue content of neutrophil myeloperoxidase (myeloperoxidase) and IL-8 was measured by ELISA. Mucosal production of oxygen-derived free radical was measured using luminol-dependent chemiluminescence (ChL). A proton pump inhibitor (either lansoprazole 30 mg, omeprazole 20 mg, or rabeprazole 10 mg) was administered daily by mouth to all patients for 8 weeks. Endoscopic examination was then repeated, and biochemical analysis was performed.


RESULTS
Antral myeloperoxidase decreased significantly after proton pump inhibitor treatment (5.23 +/- 7.00-2.76 +/- 5.11 ng/mg, P < 0.02), but corpus myeloperoxidase was unchanged. IL-8 was also modified by proton pump inhibitors and these changes were parallel to those of myeloperoxidase. Corpus ChL was significantly increased from 88.5 +/- 69.8-159 +/- 172 counts/10 s/mg after proton pump inhibitor treatment, whereas antrum ChL was not altered. H. pylori infection rate was decreased in the antrum as well as the corpus.


CONCLUSIONS
Proton pump inhibitor treatment stimulated oxygen-derived free radical production in the corpus mucosa.
Suzuki
M
M
Division of Gastroenterology, National Tokyo Medical Center, Meguro-ku, Tokyo, Japan. msuzuki@ntmc.hosp.go.jp
Suzuki
H
H
Kitahora
T
T
Miyazawa
M
M
Nagahashi
S
S
Suzuki
K
K
Ishii
H
H
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D016481:Helicobacter Infections / Q000150:complications* / Q000378:metabolism / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009195:Peroxidase / Q000378:metabolism; D054328:Proton Pump Inhibitors; D017382:Reactive Oxygen Species / Q000378:metabolism; D013276:Stomach Ulcer / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology
D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D017382:Reactive Oxygen Species; D009195:Peroxidase